July 13, 2020
Scale vs. Service? Your rare drug demands both.
When developing a drug commercialization strategy, there’s a misconception that patient service and program scalability are mutually exclusive. The prevailing…Read More
June 18, 2020
Revealing 5 hidden truths about using a hub-and-spoke model for rare and orphan drugs
The hub-and-spoke approach has become a standard of drug commercialization. Having a network of patient…Read More